DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Endoscopic Sleeve Gastroplasty saves $33,583 vs semaglutide over 5 years per JAMA 2024 data — but at lower max weight loss. Calculator shows your specific scenario across 4 paths.
ESG = one-time, GLP-1 = ongoing — but max weight loss differs
ESG procedure cost ~$10-15K once. GLP-1 ongoing $499/month cash, ~$25/month with insurance. JAMA 2024 5-year analysis: ESG $33,583 cheaper at population mean. But tirzepatide hits 22% TBL vs ESG\'s 16% — for max weight loss, GLP-1 wins. Calculator shows your specific trade-off.
Your situation
Cheapest path but regulatory risk increasing (Novo v Hims settlement, FDA 30-letter batch). Quality varies by compounding pharmacy.
Insurance: Not covered. Cash-pay only.
Outpatient endoscopic procedure stitching the stomach into a sleeve shape. No incisions. Reversible. JAMA 2024 5-year data shows 16% TBL maintained without ongoing medication cost.
Insurance: Limited — most commercial plans consider experimental. ~10% of plans cover with PA. Self-pay typical.
Weekly injection. Continuous treatment — discontinuation causes 2/3 regain within 12 months. NovoCare cash-pay $499/month standard reference.
Insurance: Insurance + PA reduces to $25-50/mo. Manufacturer cash $499/mo. TrumpRx ~$350/mo.
Weekly injection. Higher weight-loss efficacy than semaglutide. Same continuation requirement. LillyDirect cash-pay $549/month.
Insurance: Insurance + PA reduces to $25-50/mo. Manufacturer cash $549/mo. TrumpRx ~$350/mo.
ESG is performed by bariatric endoscopists at specialty centers. Bariendo operates a national DTC ESG program with transparent pricing + 5-year cost-effectiveness data.
Visit BariendoInsurance coverage of ESG varies widely. Most commercial plans consider it experimental — typical self-pay $9,000-15,000. GLP-1 + insurance can reach $25/month with PA but requires ongoing approval renewal. Calculator uses national averages — your local costs may differ.
Endoscopic Sleeve Gastroplasty — an outpatient procedure where an endoscopist places sutures inside the stomach to create a sleeve shape. No incisions, no laparoscopy. Reversible. Performed by a bariatric endoscopist. Recovery typically 1-2 days vs traditional sleeve gastrectomy weeks.
Depends on goals + timeline. For 5+ year cost: ESG often cheaper IF you can pay the upfront procedure cost ($9,000-15,000). For maximum weight loss: tirzepatide (Zepbound) wins at 22% TBL vs ESG's 16%. For risk profile: GLP-1 is reversible, ESG is harder to reverse. Most clinicians now offer both options to BMI 35-40 patients.
Limited. Most commercial plans consider ESG experimental — about 10% cover with prior authorization. Medicare doesn't cover for weight loss alone. Self-pay typical at $9,000-15,000 depending on region. Some plans cover for severe obesity with comorbidities after GLP-1 failure.
Generally no — the mechanisms overlap (both reduce gastric capacity). Most bariatric endoscopists recommend choosing one. Patients who tried GLP-1 and didn't respond well are good ESG candidates. Combined use is studied but not standard.
Several reasons: (1) no procedure required, (2) reversible, (3) growing insurance coverage with PA, (4) telehealth convenience, (5) GLP-1 has stronger cardiovascular and kidney outcomes data. ESG remains a niche option — accelerating with cost-conscious patients post-2024 JAMA cost-effectiveness data.
JAMA Network Open 2024 published 5-year cost-effectiveness comparison: ESG saved $33,583 vs semaglutide over 5 years for BMI 31.7-33 patients. ESG group had 17% TBL maintained; semaglutide group had 19% TBL but only 60% maintained therapy through 5 years (discontinuation drove cost vs outcome divergence).
Cost data based on JAMA Network Open 2024 5-year ESG vs semaglutide cost-effectiveness analysis. Your actual costs depend on insurance status, region, and treatment adherence. ESG procedure costs vary $9K-15K by city. Affiliate disclosure: we link to Bariendo + GLP-1 providers and may earn commission.